Artificial Oocyte Activation

NCT06290895 | Completed

• 1 other identifier: 3465
• Study Type: observational
• Target: 54
• Locations: 1 country
• Sites: 1

Brief Summary

Studies reported that calcium signal deficiency or insufficiency during oocyte activation are related with embryo arrest and blastocyst quality. The utilization of Artificial Oocyte Activation (AOA) is safe and does not increase birth defects, cognition, language and motor skills. AOA is the first line of treatment in patients with globozoospermia (round headed spermatozoa). Poor responders in in-vitro fertilization (IVF) cycles represent a major challenge for fertility specialists and comprises about 10-15% of patients undergoing controlled ovarian hyperstimulation. The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. The European Society of Human and REproduction (ESHRE) recommends AOA in cases with failed fertilization/ low fertilization.

Conditions

Infertility; Ovarian Insufficiency

Outcome Measures

Primary Outcomes (1)

• Blastocyst rate

  Likelihood of an oocyte fertilized to blastocyst stage

  5 days after oocyte fertilization

Study Arms (2)

In-vitro fertilization (IVF) cycle using artificial oocyte activation (AOA)

Other: women having had a second IVF cycle with AOA

In-vitro fertilization (IVF) cycle without artificial oocyte activation (AOA)

Interventions

women having had a second IVF cycle with AOA OTHER

The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. Physiological oocyte activation requires a sperm-derived enzyme called phospholipase C zeta to cause the release of calcium in the form of oscillations from internal storages.

In-vitro fertilization (IVF) cycle using artificial oocyte activation (AOA)

Eligibility Criteria

• Age: 18 Years - 42 Years
• Gender Eligibility Details: Women able to have oocyte retrieval after in-vitro fertilization
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Data spreadsheet from 2018 to 2023 of patients having undergone an IVF cycle

You may qualify if:

• Patients with poor or no blastocyst development in their primary cycle
• Group 1 - second cycle using AOA following the poor blastocyst development cycle
• Group 2 - second cycle without AOA following the poor development cycle

You may not qualify if:

• All cycles who do not have repeat cycles following the poor blastocyst development cycle

Sponsors & Collaborators

• Clinique Ovo: lead

Study Sites (1)

Clinique Ovo

Montreal, Quebec, H4P 2S4, Canada

Location

MeSH Terms

Conditions

Infertility

Condition Hierarchy (Ancestors)

Genital Diseases; Urogenital Diseases

Study Officials

• Simon Phillips, PhD

  Clinique Ovo

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 26, 2024
• First Posted: March 4, 2024
• Study Start: February 22, 2024
• Primary Completion: March 26, 2024
• Study Completion: March 26, 2024
• Last Updated: March 20, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)